Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. Issue 2 (February 2017)

• Record Type: Journal Article
• Authors: Mirza, Mansoor R.; Monk, Bradley J.; Herrstedt, Jørn; Oza, Amit M.; Mahner, Sven; Redondo, Andrés; Fabbro, Michel; Ledermann, Jonathan A.; Lorusso, Domenica; Vergote, Ignace; Ben-Baruch, Noa E.; Marth, Christian; Mądry, Radoslaw; Christensen, René D.; Berek, Jonathan S.; Dørum, Anne; Tinker, Anna V.; du Bois, Andreas; González-Martín, Antonio; Follana, Philippe; Benigno, Benedict; Rosenberg, Per; Gilbert, Lucy; Rimel, Bobbie J.; Buscema, Joseph; Balser, John P.; Agarwal, Shefali; Matulonis, Ursula A.
• Is Part Of: Obstetrical & gynecological survey. Volume 72:Issue 2(2017)
• Publication Date: 2017-02
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/OGX.0000000000000404
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from N Engl J Med 2016;375(22):2154–2164) The initial response rate to platinum and taxane treatment in patients with advanced ovarian cancer is high. However, the effectiveness of this regimen diminishes over time, and most patients relapse; with retreatment, relapses occur at shorter intervals until patient death.